Autism Spectrum Disorder Market

Autism Spectrum Disorder market

Autism Spectrum Disorder is a disorder of development that affects communication and behavior. It is a complex developmental condition that involves persistent challenges in social interaction, speech and non-verbal communication, and restricted/repetitive behaviours.

Autism Spectrum Disorder Epidemiology

Autism Spectrum Disorder total prevalent population in 7 major markets was found to be 6,585,629 in 2017.  In 2017, there were the highest cases of Autistic disorder, followed by cases of Pervasive Development Disorder in the United States.  Among the European countries, the UK had the highest Autism Spectrum Disorder prevalentpopulation, followed by Italy in 2017. On the other hand, Germany had the lowest prevalent population. Autism Spectrum Disorder affects females less frequently than males.

Autism Spectrum Disorder Market Outlook

Autism Spectrum Disorder therapeutic market in seven major markets was found to be USD 2525.2 million in 2017. The United States reports for the largest Autism Spectrum Disorder market size of USD 1372.59 million, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan. Among EU5 countries, the UK had the highest Autism Spectrum Disorder market size, while Germany had the smallest Autism Spectrum Disorder market size.

The pharmacological Autism Spectrum Disorder treatment is widely employed as an adjunctive treatment approach in the majority of individuals with Autism Spectrum Disorder across the lifespan. The best-established goals of pharmacotherapy are to control associated target symptoms, such as insomnia, hyperactivity, impulsiveness, irritability, auto, and hetero aggressiveness, inattention, anxiety, depression, obsessive symptoms, tantrums, anger attempts, and repetitive behaviours or rituals.

Autism Spectrum Disorder therapeutic market is currently dependent on “off-label” therapies mainly used to improve the signs and symptoms of the disease. The drugs commonly prescribed to Autism Spectrum Disorder patients include antipsychotics, antidepressants, selective serotonin reuptake inhibitors, stimulants, anticonvulsants, antihypertensives, CNS depressants, and others. Albeit several medications are used to treat the Autism Spectrum Disorder symptoms, such as irritability, aggression, and aberrant social behaviour, only risperidone and aripiprazole are FDA-approved for Autism Spectrum Disorder patients.

Autism Spectrum Disorder treatment

The US market has only two FDA approved therapies for the Autism Spectrum Disorder treatment, Risperidone, and Aripiprazole, developed by Johnson and Johnson and Otsuka Pharmaceutical, respectively. Risperdal (risperidone) is a novel antipsychotic belonging to a new class of antipsychotic agents, which is a benzisoxazole-derivatives. It is a selective monoaminergic antagonist with a high affinity for serotoninergic 5-HT2 and dopaminergic D2 receptors. While Abilify (aripiprazole) is a second-generation antipsychotic (SGA) or atypical antipsychotic medication, it rebalances dopamine and serotonin to improve thinking, mood, and behaviour.

The launch of various multiple-stage pipeline products will significantly revolutionize the Autism Spectrum Disorder market dynamics with the constant efforts in research and development by key players such as Roche, Finch Therapeutics, Neurochlore/Servier, Optinose, Nobelpharma, Johnson and Johnson, Vanda Pharmaceuticals, Yamo Pharmaceuticals, Curemark, and others in the near future.